ACM
REGN icon

Asymmetry Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Asymmetry Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-4,584
Closed -$1.72M – 36
2019
Q4 		$1.72M Buy
+4,584
New +$1.54M 3.08% 12
2017
Q4 		– Sell
-2,233
Closed -$998K – 36
2017
Q3 		$998K Buy
+2,233
New +$1.06M 1.16% 27

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

Asymmetry Capital Management's REGN Position: Q1 2020 in Review

Asymmetry Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2020, closing a stake of 4,584 shares — an estimated $1.72M sold.

Asymmetry Capital Management first reported a position in REGN in Q3 2017 and held it in 2 quarters. The position peaked at $1.72M in Q4 2019. 816 funds tracked by Wall St. Rank hold REGN as of Q1 2020.

  • Asymmetry Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Asymmetry Capital Management sold 4,584 Regeneron Pharmaceuticals shares in Q1 2020, an estimated $1.72M.
  • Asymmetry Capital Management first reported a position in Regeneron Pharmaceuticals in Q3 2017 and held it in 2 quarters.
  • Asymmetry Capital Management's Regeneron Pharmaceuticals position peaked at $1.72M in Q4 2019.
  • 816 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2020.

Based on Asymmetry Capital Management's 13F filing for Q1 2020, filed 13 May 2020.